Clinical trial

Empa PASS on Urinary Tract Malignancies

NCT03464045

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2016-11-16

PhaseN/A

Study timeline

Study start (actual)2016-11-16Date precision: day

Registry last updated2025-04-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Diabetes Mellitus, Type 2verified · MONDO: type 2 diabetes mellitus

Interventions

empagliflozinDRUG · verified · RxNorm: empagliflozin

DPP-4 inhibitorsDRUG

Sponsors & collaborators

Boehringer Ingelheimlead sponsor

Eli Lilly and Companycollaborator

Mapped research locations

LondonUnited Kingdom1 StockholmSweden1 HelsinkiFinland1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03464045 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.